Professor Lim Soo of Seoul National University Bundang Hospital presents an end-of-the-year paper on Nature Review

Dec 17, 2024

Professor Lim Soo of Seoul National University Bundang Hospital presents an end-of-the-year paper on Nature Review



Lim Soo, a professor of endocrine metabolism at Seoul National University Bundang Hospital (a professor of internal medicine at Seoul National University), compiled the latest research on Metabolic Syndrome in which hyperglycemia, hypertension, dyslipidemia, obesity, and arteriosclerosis appear in individuals at once and published it in a final paper in the world-class journal Nature Reviews Disease Primers.

The review paper is a paper in the form of a journal inviting the world's top authority in the field to organize the latest research trends and present directions, and it is a very meaningful achievement for domestic medical staff to publish it as a lead author in the world-renowned Nature Review journal.

The paper, published in collaboration with Professor Lim Soo and Professor Despres at the University of Laval, Canada, emphasized that △ hyperglycemia △ hypertension △ dyslipidemia △ obesity included in metabolic syndrome are not individual risk factors but work in combination with interrelationships. For example, abdominal obesity is deeply related to visceral fat accumulation, and visceral fat causes an inflammatory reaction and worsens insulin resistance, causing high blood sugar.



In particular, the research team revealed that metabolic syndrome acts as a fundamental risk factor for cardiovascular diseases such as angina, myocardial infarction, type 2 diabetes, and chronic kidney disease, reflecting the concept of 'cardiovascular-renal-metabolism' proposed by the American Heart Association, emphasizing the need for comprehensive management and prevention strategies.

In addition, the mechanism ( mechanism) of drug treatment such as GLP-1 receptor agonists and SGLT2 inhibitors, which play a particularly important role in the recent treatment of metabolic syndrome, was directly introduced by Professor Lim Soo, who led the East Asian phase 3 clinical trial of Semaglutide, an obesity drug that has recently attracted global attention.



Professor Lim Soo said, `Recently, chronic metabolic diseases such as diabetes, obesity, fatty liver, and dyslipidemia have exploded in Koreans, posing a great threat to public health"The number of diabetic patients in Korea reaches 6 million, and the proportion of overweight and obese people is serious enough to reach 30% of the total population."

Professor Lim Soo then stressed that a systematic system is desperately needed to recognize that these are not individual diseases but chronic diseases that are interrelated based on metabolic syndrome and to provide customized and integrated diagnosis and treatment.



In addition, he said, `Although drug treatment is improving a lot, it is essential for each citizen to avoid high blood sugar and high fat foods from a young age, to maintain a healthy lifestyle of exercising regularly at least three times a week while properly eating balanced foods containing protein, carbohydrates, and fat.'

Professor Lim Soo of Seoul National University Bundang Hospital presents an end-of-the-year paper on Nature Review
임수 교수


bellho@sportschosun.com